Abata Therapeutics

Senior Scientist, Clinical Pharmacology

Remote

Not SpecifiedCompensation
Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, PharmaceuticalsIndustries

Requirements

Candidates should possess a Bachelor's degree and 10 years of experience, or a Master's degree and 8 years of experience in life sciences, pharmaceutical sciences, or pharmacology. A strong background in conducting clinical pharmacology studies, including study design, PKPD data analysis, and interpretation of results, is essential. A PhD in Pharmaceutical Science or a related discipline is preferred, along with strong quantitative experience such as pharmacometrics.

Responsibilities

The Senior Scientist, Clinical Pharmacology will be responsible for pharmacokinetic modeling and analyzing clinical PK data using non-compartmental analysis. This role involves engaging in translational research, exploring exposure/response relationships, and developing models using preclinical and clinical data to assess treatment strategies. Key duties include designing and implementing clinical modeling, authoring clinical pharmacology documents, performing PK data analysis, influencing the development of drugs through model-informed drug development (MIDD), managing external vendors for PKPD analyses, supporting internal modeling efforts, contributing to the improvement of tools and processes, managing translational research with collaborators, and influencing the external scientific environment through publications and presentations.

Skills

Pharmacokinetic modeling
Non-compartmental analysis
Translational research
Exposure/response relationships
Clinical development plans

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters
2021Year Founded
$184.8MTotal Funding
EARLY_VCCompany Stage
BiotechnologyIndustries
11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.
Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.
Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.
Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.
Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.
FDA's accelerated approval pathways may expedite Abata's clinical trials.
Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI